Ascendis Pharma A/s (ASND) annual income statement covering fiscal 2015 through 2017, as reported to the SEC. This statement has 2 line items across 3 periods.
An income statement shows what a company sold and what it cost to run the business, ending with the profit left over.
| Dec'17 | Dec'16 | Dec'15 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other comprehensive income / (loss) | ||||||||||||||||||
Items that may be reclassified subsequently to profit or loss: | ||||||||||||||||||
Number of shares used for calculation (basic and diluted) | ||||||||||||||||||
33,626 | 26,564 | 23,766 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Number of shares used for calculation (basic and diluted) | 33,626 | 26,564 | 23,766 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Number of shares used for calculation (diluted) | ||||||||||||||||||
33,626 | 26,564 | 23,766 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Number of shares used for calculation (diluted) | 33,626 | 26,564 | 23,766 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||